Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Published online May 16, 2007
Diabetes Care 30:2302-2306, 2007
DOI: 10.2337/dc07-0225
© 2007 by the American Diabetes Association
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dc07-0225v1
30/9/2302    most recent
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Perumalsamy, N.
Right arrow Articles by Ramasamy, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Perumalsamy, N.
Right arrow Articles by Ramasamy, K.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Emerging Treatments and Technologies
Original Article

Software for Reading and Grading Diabetic Retinopathy

Aravind Diabetic Retinopathy Screening 3.0

Namperumalsamy Perumalsamy, MD1, Noela M. Prasad, MSC1, Shankar Sathya, BE2 and Kim Ramasamy, MD1

1 Aravind Eye Care System, Madurai, India
2 Eagle Software, Santa Ana, California

Address correspondence and reprint requests to Noela M. Prasad, Aravind Eye Care System, 1, Annanagar, Madurai 625 020, India. E-mail: noelaprasad{at}yahoo.co.in

OBJECTIVE—To evaluate the validity and reproducibility of software for reading digital images and grading diabetic retinopathy.

RESEARCH DESIGN AND METHODS—A prospective, comparative observational study was conducted on a series of patients with type 2 diabetes who presented at the retina clinic of a tertiary care center in India. A total of 210 eyes of 105 patients were allocated to one of three ophthalmologists, who performed dilated indirect and direct ophthalmoscopy and subsequently assessed the digital images of the same group of patients who were masked to the patient's identity. The interobserver and intertest agreement between clinical assessments and grading of diabetic retinopathy using the software was estimated.

RESULTS—Moderate nonproliferative diabetic retinopathy (NPDR) was most frequently diagnosed, both clinically and on evaluating digital images. The overall agreement between the clinical grading of diabetic retinopathy and the grading of images was 81.3% ({kappa} = 0.69, SE 0.04, P < 0.0001); there was good agreement (81.3%) for NPDR ({kappa} = 0.61, SE 0.05, P < 0.0001), but agreement was not as good (54.6%) for proliferative diabetic retinopathy ({kappa} = 0.29, SE 0.11, P = 0.005). Clinically significant macular edema was diagnosed in 33.3% (70 of 210) of eyes clinically and in 40.2% (84 of 209) of eyes by grading images, and there was good agreement (89.5%) between the two ({kappa} = 0.77, SE 0.07, P < 0.0001).

CONCLUSIONS—Aravind Diabetic Retinopathy Screening 3.0 is a simple and valid tool to assist in the detection of sight-threatening retinopathy and could supplement dilated fundus examinations by ophthalmologists on patients to detect diabetic retinopathy.

Abbreviations: ADRES, Aravind Diabetic Retinopathy Screening • CSME, clinically significant macular edema • NPDR, nonproliferative diabetic retinopathy • PDR, proliferative diabetic retinopathy


Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 2007 by the American Diabetes Association.